ContraVir Pharmaceuticals Inc Share Price OTC Bulletin Board
Equities
US21234W1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
21/05 | Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
22/04 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 1.41Cr 117.38Cr |
---|---|---|---|---|---|
Net income 2022 | -4.2Cr -350.78Cr | Net income 2023 | -4.8Cr -400.89Cr | EV / Sales 2022 | - |
Net cash position 2022 | 5.11Cr 427.07Cr | Net cash position 2023 | 1.46Cr 121.74Cr | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.5
x | P/E ratio 2023 |
-0.26
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.28% |
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01/16/01 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03/19/03 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15/13/15 |
Timothy Block
BRD | Director/Board Member | 69 | 26/13/26 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27/22/27 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 13TCr | |
+24.67% | 12TCr | |
+25.44% | 2.79TCr | |
-17.74% | 2.1TCr | |
-15.17% | 1.69TCr | |
-15.21% | 1.62TCr | |
+11.91% | 1.48TCr | |
-47.10% | 1.48TCr | |
+54.50% | 1.41TCr |